High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up

INTRODUCTION: To evaluate the oncological outcome of high dose rate (HDR) brachytherapy (BRT) as monotherapy for clinically localised prostate cancer (PCA). MATERIAL AND METHODS: Between January 2002 and February 2004, 141 consecutive patients with clinically localised PCA were treated with HDR-BRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Behmueller, Manuel, Tselis, Nikolaos, Zamboglou, Nikolaos, Zoga, Eleni, Baltas, Dimos, Rödel, Claus, Chatzikonstantinou, Georgios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674679/
https://www.ncbi.nlm.nih.gov/pubmed/34926278
http://dx.doi.org/10.3389/fonc.2021.770959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8674679/
https://www.ncbi.nlm.nih.gov/pubmed/34926278
http://dx.doi.org/10.3389/fonc.2021.770959

Ejemplares similares